Genomics in the kidney transplant clinic: the future standard of care?

Abstract

New evidence indicates potential benefit of genomics to illuminate nonkidney monogenic morbidity and mortality risk among kidney transplant recipients. This might be of direct relevance to an equivalent proportion of patients to those who harbor a monogenic kidney disease. Further evidence and replication are indicated, including a broadening potential range of monogenic and polygenic opportunities to improve clinical outcomes. Implementation will require such information, although it holds great promise.